Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990)
460.00
+11.00 (2.45%)
At close: Dec 5, 2025
HKG:6990 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Cash & Equivalents | 3,103 | 1,337 | 1,529 | 92.96 | 81.79 |
| Short-Term Investments | 559.05 | 283.98 | 325.87 | - | - |
| Trading Asset Securities | 852.34 | 1,448 | 633.71 | - | - |
| Cash & Short-Term Investments | 4,514 | 3,069 | 2,488 | 92.96 | 81.79 |
| Cash Growth | 56.46% | 23.33% | 2576.80% | 13.65% | - |
| Accounts Receivable | 207.1 | 60.76 | 1.35 | 61.8 | 22.73 |
| Other Receivables | 198.29 | 183.33 | 123.1 | 42.63 | 47.83 |
| Receivables | 405.39 | 244.09 | 124.45 | 104.43 | 70.56 |
| Inventory | 200.2 | 110.51 | 63.03 | 52.64 | 50.72 |
| Prepaid Expenses | 0.11 | 2.09 | 35.65 | - | - |
| Other Current Assets | 72.78 | 67.33 | 96.01 | 82.29 | 95.27 |
| Total Current Assets | 5,193 | 3,493 | 2,807 | 332.32 | 298.34 |
| Property, Plant & Equipment | 741.35 | 758.11 | 692.73 | 647.82 | 474.17 |
| Other Intangible Assets | 1.7 | 2.58 | 1.34 | 3.18 | 0.49 |
| Other Long-Term Assets | 17.17 | 14.51 | 8.2 | 9.83 | 39.97 |
| Total Assets | 5,953 | 4,268 | 3,510 | 993.15 | 812.96 |
| Accounts Payable | 364.76 | 291.29 | 404.38 | 327.46 | 325.28 |
| Accrued Expenses | 106.31 | 156.34 | 133.77 | 86.61 | 44.72 |
| Short-Term Debt | - | - | - | 2,891 | 2,388 |
| Current Portion of Leases | 43.96 | 41.84 | 54.41 | 82.26 | 1.66 |
| Current Income Taxes Payable | 4.25 | 5.46 | 3.73 | 2.7 | 2.52 |
| Current Unearned Revenue | 261.81 | 312.38 | 510.69 | 163.98 | 109.04 |
| Other Current Liabilities | 9.26 | 2.54 | 3.03 | 613.57 | 573.72 |
| Total Current Liabilities | 790.35 | 809.84 | 1,110 | 4,167 | 3,445 |
| Long-Term Leases | 87.12 | 84.91 | 5.51 | 41.29 | 1.25 |
| Long-Term Unearned Revenue | 61.12 | 64.6 | 64.74 | 10.68 | 10.68 |
| Total Liabilities | 938.6 | 959.34 | 1,180 | 4,219 | 3,457 |
| Common Stock | 233.19 | 227.27 | 219.2 | 107.37 | 107.37 |
| Retained Earnings | -4,468 | -4,323 | -4,056 | -3,482 | -2,866 |
| Comprehensive Income & Other | 9,249 | 7,404 | 6,167 | 148.63 | 114.83 |
| Shareholders' Equity | 5,014 | 3,309 | 2,329 | -3,226 | -2,644 |
| Total Liabilities & Equity | 5,953 | 4,268 | 3,510 | 993.15 | 812.96 |
| Total Debt | 131.08 | 126.75 | 59.92 | 3,014 | 2,391 |
| Net Cash (Debt) | 4,383 | 2,942 | 2,428 | -2,921 | -2,309 |
| Net Cash Growth | 53.96% | 21.15% | - | - | - |
| Net Cash Per Share | 19.43 | 13.27 | 13.22 | -30.58 | -24.98 |
| Filing Date Shares Outstanding | 233.19 | 227.27 | 219.2 | 215.83 | 92.46 |
| Total Common Shares Outstanding | 233.19 | 227.27 | 219.2 | 107.37 | 92.46 |
| Working Capital | 4,402 | 2,683 | 1,697 | -3,835 | -3,147 |
| Book Value Per Share | 21.50 | 14.56 | 10.63 | -30.05 | -28.60 |
| Tangible Book Value | 5,013 | 3,306 | 2,328 | -3,229 | -2,644 |
| Tangible Book Value Per Share | 21.50 | 14.55 | 10.62 | -30.08 | -28.60 |
| Buildings | - | 294.1 | 294.4 | - | - |
| Machinery | - | 324.51 | 262.26 | 221.56 | 200.16 |
| Construction In Progress | - | 88.11 | 119.99 | 348.59 | 282.36 |
| Leasehold Improvements | - | 16.47 | 14.45 | 13.67 | 0.38 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.